How to Introduce Multi-Indication Based Pricing in Finland? Objectives: Access to new treatment options is of pivotal importance to cancer patients. In 2017, around 50% of cancer medicines had more than one indication, and that number is estimated to be 75% in 2020. The value of several cancer drugs differs between indications. In Finland, the Pharmaceutical Pricing Board evaluates the value of drugs per indication, but the current system does not allow different prices for different indications, which may delay the patient access to lower-value indications. This study explored possibilities to implement multi-indication pricing to the Finnish P&R system. Methods: Desktop research and interviews with key stakeholders to explore opportunities for multi-indication pricing in the current pricing and reimbursement system. Results: To apply multi-indication or combination pricing schemes, a data infrastructure to track patients’ indications and the number of patients per indication is needed. Today, the Social Insurance Institution of Finland (Kela) issues reimbursement numbers to reimbursed medicines (one number per medicine or group of medicines indicated for a certain disease). Customers get reimbursement directly at the pharmacy based on their eligibility for reimbursement. Information about the purchase and reimbursement is transmitted directly from the pharmacy to Kela’s national database. Should Kela allow separate reimbursement numbers for different indications, the system could track the number of patients per indication and their treatment duration. Finland has recently introduced conditional reimbursement, which enables manage entry agreements with risk sharing. Combined with separate reimbursement numbers for different indications, these elements would enable multi-indication pricing in Finland, while the medicines would still have one list price. Conclusion: This study suggests that as part of the newly introduced conditional reimbursement in Finland, multi-indication based pricing could be implemented. This would put Finland at the forefront in the early and improved patient access in lower-value indications.